PR Newswire (Thu, 4:39PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
141 people get HAE articles and Market Currents by email alert.
Get email alerts on HAE »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (May 1, 2013)
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 1, 2013)
-
PR Newswire (Feb 25, 2013)
-
PR Newswire (Feb 14, 2013)
-
PR Newswire (Feb 13, 2013)
-
PR Newswire (Feb 6, 2013)
-
PR Newswire (Jan 9, 2013)
-
PR Newswire (Jan 4, 2013)
-
PR Newswire (Dec 21, 2012)
-
-
PR Newswire (Dec 3, 2012)
To learn more about Seeking Alpha Pro, click here.
-
No Bleeding at HaemoneticsDavid Greene • Mon, Aug 23, 2010 -
Haemonetics: Q3 Results MixedZacks Investment Research • Mon, Mar 15, 2010 -
Sticking with HaemoneticsRobert Freedland • Tue, May 5, 2009 -
Haemonetics: About to Start Bleeding Profits?Joe Kunkle • Fri, Oct 17, 2008 -
Haemonetics Corporation: Market Leader in Blood RecyclingThe Wall Street Transcript • Mon, Apr 30, 2007 -
-
-
6 Low-Debt And Liquid Small Cap Healthcare StocksZetaKap • Fri, Aug 24, 2012 -
5 Highly Liquid Medical Device Stocks With Encouraging Receivable TrendsKapitall • Tue, Jul 24, 2012 -
Billionaire Jim Simons And Insiders Are Bullish About These StocksInsider Monkey • Thu, Dec 8, 2011 -
10 Oversold, No Debt Stocks Operating With Impressive ProfitabilityFollow My Alpha • Mon, Nov 21, 2011 -
Options Traders Are Bullish On These 20 Healthcare StocksKapitall • Wed, Nov 2, 2011
-
10 Oversold, Profitable Firms Trading Near 52-Week LowsFollow My Alpha • Wed, Oct 26, 2011
-
-
-
-
-
-
-
-
-
Haemonetics Receives ApprovalZacks Investment Research • Wed, Feb 24, 2010
-
-
-
Activist Investments in September 2009Greenbackd • Thu, Oct 15, 2009
-
-
Haemonetics Corporation - Analyst/Investor DayThu, May 16
-
Haemonetics Corporation F3Q09 Earnings Call TranscriptMon, Feb 2, 2009
-
Haemonetics Corp. F4Q08 (Qtr End 03/29/08) Earnings Call TranscriptFri, May 16, 2008
-
Haemonetics Corp. F4Q08 (Qtr End 03/29/08) Earnings Call TranscriptTue, May 13, 2008
-
PR Newswire (Thu, 4:39PM)
-
PR Newswire (May 1, 2013)
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 1, 2013)
-
PR Newswire (Feb 25, 2013)
-
PR Newswire (Feb 14, 2013)
-
PR Newswire (Feb 13, 2013)
-
PR Newswire (Feb 6, 2013)
-
PR Newswire (Jan 9, 2013)
-
PR Newswire (Jan 4, 2013)
-
PR Newswire (Dec 21, 2012)
-
at MarketWatch.com (Dec 4, 2012)
-
PR Newswire (Dec 3, 2012)
-
PR Newswire (Oct 19, 2012)
-
PR Newswire (Oct 18, 2012)
-
PR Newswire (Oct 4, 2012)
-
PR Newswire (Sep 25, 2012)
HAE vs. ETF Alternatives
Company Description
Our Company was founded in 1971 and became publicly owned for the first time in 1979. In 1983, American Hospital Supply Corporation (“AHS”) acquired us. When Baxter Travenol Laboratories, Inc. (“Baxter”) acquired AHS in 1985, Baxter divested the Haemonetics business to address antitrust concerns... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 1, 7:24 AM Haemonetics (HAE): FQ4 EPS of $0.48 beats by $0.02. Revenue of $249.9M (+34% Y/Y) beats by $0.57M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, January 30, 10:13 AM Haemonetics (HAE -8.4%) slides after reporting a mixed FQ3, beating on the bottom line but coming up short on top line revenue. Total sales increased by 19% Y/Y, with organic revenue growth of 11% in Asia and 2% in Europe. which were partially offset by declines of 1% in North America and 2% in Japan. The company reaffirms its outlook for FY13, expecting an EPS of $1.65 - $1.70 on revenues of $888M - $898M, below the Street view for an EPS of $1.70 on revenues of $900M. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, January 30, 6:07 AM Haemonetics (HAE): FQ3 EPS of $0.5 beats by $0.02. Revenue of $247.4M (+19% Y/Y) misses by $4.53M. (PR) Comment! [Earnings, Healthcare, Breaking News]
- Tuesday, October 30, 2012, 2:49 PM Haemonetics (HAE) Q2 results came in mixed late yesterday, beating on a per share basis, but coming up slight shy on the revenue side. Total revenue was up nearly 22% Y/Y however, on continued strength in across its entire product portfolio. Barrington thinks the quarter was strong believes that its integration of PALL is proceeding better than expected. The firm raised its target on the stock to $88 from $79 yesterday and reiterates an Outperform on the stock. Comment! [Earnings]
- Monday, October 29, 2012, 6:26 AM Haemonetics (HAE): Q3 EPS of $0.90 beats by $0.13. Revenue of $218.2M (+21.6% Y/Y) misses by $5M. The company announces two-for-one split. (PR) Comment! [Earnings, Healthcare]
- Tuesday, September 18, 2012, 2:02 PM Haemonetics (HAE -0.4%) says its proposed acquisition of Hemerus Medical will likely be put off until next March after the start of its 2014 fiscal year. The company notes that U.S. regulators are asking for more information about its SOLX whole-blood collection system as part of a resubmitted marketing application. Comment! [Healthcare, M&A]
- Monday, April 30, 2012, 6:11 AM Haemonetics (HAE): Q1 EPS of $0.80 misses by $0.03. Revenue of $186.7M (+9.8% Y/Y) beats by $3M. (PR) Comment! [Earnings, Healthcare]
- Monday, April 30, 2012, 3:24 AM Pall Corp (PLL) said yesterday it will sell some of its blood collection, filtration and processing product lines to Haemonetics Corp (HAE) for ~$550M. Separately, Haemonetics announced it will acquire the business assets of Hemerus Medical, a company that develops innovative blood technologies. Comment! [M&A, Healthcare]
- Monday, January 30, 2012, 8:08 AM Haemonetics (HAE): FQ3 EPS of $0.86 beats by $0.80. Revenue of $191.2M (+8.1% Y/Y) beats by $5M. (PR) Comment! [Earnings, Healthcare]
- Monday, October 31, 2011, 12:41 PM Medical device manufacturer Haemonetics (HAE -3.5%) gets hit after its FQ2 misses EPS estimates, despite beating on revenue. Profits rose 8% Y/Y, but net income declined 35% due to quality issues with its HS Core Bowl and the recall of its OrthoPAT device. Comment! [Healthcare, On the Move]
- Monday, August 1, 2011, 10:47 AM Medical device maker Haemonetics (HAE -7%) takes a hit as its FQ1 earnings miss the mark due to a product recall. The company also reduces FY guidance, citing "significant headwinds" it faces over regulatory and economic concerns. Comment! [Healthcare, Earnings, On the Move]
- Monday, November 1, 2010, 8:08 AM Haemonetics (HAE): FQ2 EPS of $0.80 beats by $0.04. Revenue of $167M (+6.2%) vs. $174M. (PR) Comment!
- Monday, November 1, 2010, 12:05 AM Notable earnings before Monday's open: AAWW, ACOR, ACV, AGN, ALR, BHI, CNA, CNL, CTB, CTSH, ENDP, GLW, HAE, HUM, ICE, IPGP, JKS, L, MCY, PTV, RE, SNH, SPG, WRI Comment!
-
Ocean Man
Sold $HAE for a gain of 4.5% in 2 weeks. $37.98 ---> $39.71. http://seekingalpha.com/s/egxax - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES